New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
Retrieved on:
Friday, July 31, 2020
The OPTIC 24-week treatment period evaluated patients who received TEPEZZA or placebo once every three weeks for a total of eight infusions.
Key Points:
- The OPTIC 24-week treatment period evaluated patients who received TEPEZZA or placebo once every three weeks for a total of eight infusions.
- At Week 24 of OPTIC, proptosis responders entered into a 48-week off-treatment follow-up period, without receiving additional TED treatment, including TEPEZZA.
- Similar durability from Week 24 to Week 72 was demonstrated for other endpoints in the OPTIC 48-week off-treatment follow-up period, including diplopia and CAS.
- Of these, two achieved a 2 mm or more proptosis reduction in OPTIC-X after an additional course of TEPEZZA.